Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

An Artificial Intelligence-Powered Supportive Care Chatbot to Address the Supportive Care Needs of Young Adult Cancer Survivors

13. august 2026 oppdatert av: University of Michigan Rogel Cancer Center

Feasibility, Usability, and Acceptability of an AI-Powered MASCC Supportive Care Platform Among Young Adults With Cancer

This clinical trial studies whether an artificial intelligence (AI)-powered supportive care chatbot is helpful for addressing the supportive care needs of young adult cancer survivors. Young adult cancer survivors often experience ongoing and distressing symptoms following treatment, including extreme tiredness and lack of energy, anxiety, and difficulty sleeping. Young adult cancer survivors report a variety of strategies to self-manage these symptoms; however, there remains a gap in targeted interventions focused on the needs in young adult survivors. The AI-powered supportive care chatbot is designed to provide evidence-based information on supportive care for young adult cancer survivors. Users interact with the chatbot by entering free-text questions or selecting from predefined topics to receive tailored educational responses related to supportive care across the cancer continuum, including treatment effects, symptom management, care transitions, and life after cancer. The AI-powered supportive care chatbot may be an effective way to help address the supportive care needs of young adult cancer survivors.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

30

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • University of Michigan Rogel Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Robert Knoerl

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • 18 - 39 years old
  • Able to speak/read English
  • Completed primary cancer treatment (e.g., surgery, radiation, chemotherapy, immunotherapy) at least one month prior to the time of consent. Although, participants will be eligible if they are receiving maintenance treatments
  • Report at least one moderate to severe symptom, side effect, or supportive care concern from cancer or its treatment
  • Able to access Wi-Fi/internet
  • Willing to complete surveys electronically

Exclusion Criteria:

  • Completed cancer treatment more than three years ago

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Supportive care (AI-powered supportive care chatbot)
Patients interact with AI-powered supportive care chatbot in a self-directed manner for 4 weeks. Following the initial 4-week use period, patients choose to either continue to use the chatbot for an additional 8 weeks or conclude study participation.
Hjelpestudier
Hjelpestudier
Interact with AI-powered supportive care chatbot
Andre navn:
  • AI Intervention
  • AI-based Intervention

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Acceptability of AI-powered supportive care chatbot
Tidsramme: At end of intervention, assessed up to 12 weeks
Acceptability will be supported if mean scores on the Acceptability E-Scale are ≥ 4 (on a 5-point scale). Will be described (i.e., means, medians, standard deviations, and ranges) at the post-intervention time point.
At end of intervention, assessed up to 12 weeks
Demand of AI-powered supportive care chatbot
Tidsramme: Up to 12 months
Demand will be demonstrated by successful recruitment of the target sample (N=30) within 12 months.
Up to 12 months
Implementation of AI-powered supportive care chatbot
Tidsramme: During intervention use, assessed up to 12 weeks
Implementation will be assessed by engagement with the chatbot, defined as ≥ 70% of participants reporting at least one use per week during the initial 4-week period, rather than a fixed duration of use, given the self-directed nature of the intervention. Will be described (i.e., means, medians, standard deviations, and ranges) weekly. Given the pilot nature of the study, no hypothesis testing or formal comparisons will be conducted.
During intervention use, assessed up to 12 weeks
Retention
Tidsramme: Up to 12 weeks
Retention will be considered feasible if ≥ 80% of participants complete 4-week assessments, and ≥ 50% elect to continue to the optional extended use period.
Up to 12 weeks
Usability of AI-powered supportive care chatbot
Tidsramme: At end of intervention, assessed up to 12 weeks
Usability will be supported if mean System Usability Scale scores are ≥ 70, indicating acceptable usability. Will be described (i.e., means, medians, standard deviations, and ranges) at the post-intervention time point.
At end of intervention, assessed up to 12 weeks
Patient Reported Outcomes Measurement Information System measure
Tidsramme: At baseline, 4 weeks, and/or 12 weeks
Will be summarized using descriptive statistics (e.g., means, medians, standard deviations, and ranges) at each time point. Changes over time (baseline, post-intervention, as applicable) will be examined descriptively.
At baseline, 4 weeks, and/or 12 weeks
Digital Health Literacy Scale
Tidsramme: At baseline
Will be summarized using descriptive statistics (e.g., means, medians, standard deviations, and ranges) at the baseline time point. The Digital Health Literacy Scale is a 0 to 12 point score (based on 3 items), with higher scores indicating greater digital health care literacy.
At baseline
Interview themes and subthemes
Tidsramme: At end of intervention, assessed up to 12 weeks
The audio-recorded interviews will be transcribed verbatim by a professional transcription company and verified for accuracy by another study team member. The finalized transcripts will be imported into NVivo 12 (QSR International Pty Ltd). Inductive content analysis will be used to analyze the interview transcripts. Two study team members will review the transcripts and the interview guide to create an initial list of codes. Three transcripts will be independently coded using the initial codebook. After three interviews are coded, two study team members will meet to resolve any coding discrepancies and to revise the codebook further. The same process will be repeated after three more interviews are coded. After the codebook is finalized, one study team member will code the remaining interviews. Subsequently, the study team will meet as a group to review the transcripts in their entirety, making sense of the data and generating potential major themes and subthemes.
At end of intervention, assessed up to 12 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Robert Knoerl, University of Michigan Rogel Cancer Center

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. oktober 2026

Primær fullføring (Antatt)

1. oktober 2028

Studiet fullført (Antatt)

1. oktober 2028

Datoer for studieregistrering

Først innsendt

30. juli 2026

Først innsendt som oppfylte QC-kriteriene

13. august 2026

Først lagt ut (Faktiske)

19. august 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. august 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • UMCC 2026.025
  • NCI-2026-05454 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
  • HUM00288074 (Annen identifikator: University of Michigan Rogel Cancer Center)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified participant data will be shared with other researchers upon reasonable request and execution of a data transfer agreement.

IPD-delingstidsramme

After publication of results and within 7 years after study completion.

Tilgangskriterier for IPD-deling

De-identified participant data will be shared with other researchers upon reasonable request and execution of a data transfer agreement.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • ANALYTIC_CODE
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere